Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Size (2024 - 2029)

The market size for Viral Vector Contract Development and Manufacturing Organizations is projected to experience significant growth over the forecast period, driven by initiatives from key industry players and increased government investments in innovative technologies and manufacturing facilities. The biopharma industry's demand for viral vectors, particularly for cell and gene therapies, is prompting contract manufacturers to enhance their capabilities, which is expected to further propel market expansion. Additionally, the potential of viral vectors in oncology treatments is anticipated to boost their adoption in therapy design, contributing to market growth. However, challenges related to the development and manufacturing processes, along with high costs, may pose obstacles to sustained market expansion.

Home Market Analysis Healthcare Research Biotechnology Research Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Market Size

Market Size of Viral Vector Contract Development And Manufacturing Organization (CDMO) Industry

Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 0.86 Billion
Market Size (2029) USD 2.07 Billion
CAGR (2024 - 2029) 19.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Analysis

The Viral Vector Contract Development And Manufacturing Organization Market size is estimated at USD 0.86 billion in 2024, and is expected to reach USD 2.07 billion by 2029, growing at a CAGR of 19% during the forecast period (2024-2029).

Some of the key factors driving market growth include programs launched by key players in viral vector development and increasing investments by the government to create innovative technologies and manufacturing facilities.

Contract manufacturers are actively building up their capabilities as the biopharma industry suffers from a severe lack of viral vectors for cell and gene therapies. In March 2023, Sartorius agreed to acquire French startup Polyplus for EUR 2.4 billion (USD 2.6 billion). This indicates the biopharma industry’s increasing investments in cell and gene therapy production. Such activities in the CDMO space are expected to fuel market growth in the coming years.

According to the study published in the Radiology and Oncology Journal in February 2022, the use of viral vectors to treat cancer has the potential to change the area of oncology. Virus vectors, in particular, provide a unique mix of effective gene delivery and immune system engagement for anti-tumour responses. Such studies are expected to lead to the increased adoption of viral vector manufacturing in designing therapies for cancer, driving market growth.

However, challenges associated with the viral vector contract development and manufacturing, along with high costs, are some factors expected to hinder the market’s growth in the long run.

Viral Vector Contract Development and Manufacturing Organization (CDMO) Industry Segmentation

Viral vector CDMOs are contract manufacturing and development organizations specializing in viral vector product manufacturing, which has wide applications across various disease areas, including cancer and infectious diseases.

The viral vector CDMO market is segmented by culture type, application, end user, and geography. By workflow, the market is segmented into upstream processing and downstream processing. By culture type, the market is segmented into adherent culture and suspension culture. By application, the market is segmented into cell & gene therapy development, vaccine development, biopharmaceutical & pharmaceutical discovery, and biomedical research. By end user, the market is segmented into pharmaceutical & biopharmaceutical companies and academic & research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for all the above segments.

By Vector Type
Adenovirus
Retrovirus
Adeno-Associated Virus
Lentivirus
Others
By Workflow
Upstream Manufacturing
Downstream Manufacturing
By Application
Antisense & RNAi Therapy
Gene Therapy
Cell Therapy
Vaccinology
Other Applications
By End User
Pharmaceutical & Biopharmaceutical Companies
Academic and Research Institutes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Size Summary

The viral vector contract development and manufacturing organization market is poised for substantial growth, driven by increasing investments and advancements in gene therapy technologies. The biopharma industry is experiencing a significant demand for viral vectors, particularly for cell and gene therapies, prompting contract manufacturers to enhance their capabilities. Key players in the industry are actively engaging in strategic acquisitions and partnerships to bolster their production capacities. The market is witnessing a surge in funding from both private and government sectors, aimed at fostering innovation and expanding manufacturing facilities. This influx of investment is expected to propel the market forward, with a particular focus on adeno-associated virus (AAV) segments, which are gaining traction due to their potential in gene therapy applications.

The United States is anticipated to maintain a dominant position in the North American viral vector CDMO market, supported by a robust biotech industry and a growing disease burden. The market landscape is moderately competitive, with several global players vying for market share. Companies are increasingly focusing on securing funding to meet manufacturing demands and expand their service offerings. Recent developments, such as the establishment of new CDMOs and the introduction of advanced viral vector platforms, underscore the dynamic nature of the market. These initiatives are expected to drive the adoption of viral vector manufacturing, particularly in oncology and precision medicine, despite challenges related to high costs and technical complexities.

Explore More

Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Programs by the Companies for Viral Vector Production

      2. 1.2.2 Government Support For Viral Vector CDMOs

    3. 1.3 Market Restraints

      1. 1.3.1 Challenges Faced By CDMOs

      2. 1.3.2 High Cost Associated With CDMO Establishment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size - Value in USD)

    1. 2.1 By Vector Type

      1. 2.1.1 Adenovirus

      2. 2.1.2 Retrovirus

      3. 2.1.3 Adeno-Associated Virus

      4. 2.1.4 Lentivirus

      5. 2.1.5 Others

    2. 2.2 By Workflow

      1. 2.2.1 Upstream Manufacturing

      2. 2.2.2 Downstream Manufacturing

    3. 2.3 By Application

      1. 2.3.1 Antisense & RNAi Therapy

      2. 2.3.2 Gene Therapy

      3. 2.3.3 Cell Therapy

      4. 2.3.4 Vaccinology

      5. 2.3.5 Other Applications

    4. 2.4 By End User

      1. 2.4.1 Pharmaceutical & Biopharmaceutical Companies

      2. 2.4.2 Academic and Research Institutes

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Viral Vector Contract Development And Manufacturing Organization (CDMO) Market Size FAQs

The Viral Vector Contract Development And Manufacturing Organization Market size is expected to reach USD 0.86 billion in 2024 and grow at a CAGR of 19% to reach USD 2.07 billion by 2029.

In 2024, the Viral Vector Contract Development And Manufacturing Organization Market size is expected to reach USD 0.86 billion.

Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Report Snapshots

Viral Vector Contract Development and Manufacturing Organization (CDMO) Market Size & Share Analysis - Growth, Trends & Forecasts (2024-2029)